Our motivation was to overcome what we anticipated would be limitations of scFv-based BCMA CARs: namely low antigen density of BCMA resulting in suboptimal signaling, and tumor escape through loss of BCMA. This evidence concerns the gene TNFRSF17 and neoplasm.